Table 1.

Overview of the study phases and groups, examination time points, and assessments.

			T0a		Intervention phaseb				T1c		Follow-up phaseb				T2d
					IGe (T0-T1)		CGf (T0-T1)				IG (T1-T2)		CG (T1-T2)
Enrollment
	Informed consent	✓
	Eligibility criteria	✓
	Randomization (stratified)	✓
	Training group allocation	✓						✓
Questionnaires
	Nijmegen questionnaire	✓						✓						✓
	DSQ-SF-PEMg questionnaire	✓						✓						✓
	Canadian Consensus Criteria	✓												✓
	Bell scale	✓												✓
	Brief Symptom Inventory–18	✓						✓						✓
	Insomnia Severity Index	✓						✓						✓
	Perceived Social Support Questionnaire	✓						✓						✓
	Optimism-Pessimism Short Scale–2	✓						✓						✓
	General Self-Efficacy Scale	✓						✓						✓
	Satisfaction evaluation													✓
Clinical assessments
	Anamnesish	✓
	Anthropometric datai	✓						✓						✓
	ECGj	✓						✓						✓
	Blood pressure	✓						✓						✓
	Pulmonary function test	✓						✓						✓
	Clinical examinationh	✓
	Blood biomarkersk	✓						✓						✓
	Hyperspectral imagingl													✓
	Blood gas analysis													✓
Cardiopulmonary exercise testing
	Spiroergometry	✓						✓						✓
	Lactate and cfDNAm diagnosticsn	✓						✓						✓
Muscle strength testing
	Hand grip strength	✓						✓						✓
Intervention
	Telerehabilitationo			✓								✓

^aT0: baseline assessment.

^b8 weeks.

^cT1: primary assessment.

^dT2: follow-up assessment.

^eIG: intervention group.

^fCG: control group.

^gDSQ-SF-PEM: DePaul Symptom Questionnaire–Short Form for Postexertional Malaise.

^hConducted by a study physician.

ⁱWeight, height, and body composition.

^jECG: electrocardiography.

^kThe complete list of blood biomarkers can be found in Multimedia Appendix 2.

^lOptical peripheral microcirculatory analysis.

^mcfDNA: cell-free DNA.

ⁿCapillary lactate (mmol/L) concentration and venous cfDNA concentration (ng/mL).

^oWeekly teleconsultations and web-based exercise and respiratory therapy.